Mitsubishi Tanabe Pharma
Research-driven pharmaceutical company conducting discovery, development, manufacturing, regulatory submissions, and global commercialization across small molecules, biologics, vaccines, gene/cell therapies and drug-delivery systems. Operates global R&D and clinical development programs, maintains manufacturing and vaccine production partnerships, and publishes clinical-trial information and sustainability reporting.
Industries
Nr. of Employees
Very Large (1000+)
Products
TALION AR
Allergic rhinitis medicine containing bepotastine besilate as a second-generation antihistamine, providing relief for sneezing, running nose, and stuffy nose.
タリオンAR
花粉やハウスダストなどによるくしゃみ、鼻みず、鼻づまりなどの鼻のアレルギー症状を緩和する、眠気の少ない第2世代抗ヒスタミン薬です。
タリオンＡＲ
アレルギー専用鼻炎薬。花粉やハウスダストなどによるくしゃみ、鼻みず、鼻づまりの症状を緩和します。ベポタスチンベシル酸塩を医療用と同成分・同量配合した第2世代抗ヒスタミン薬です。
タリオン錠
タリオン錠はベポタスチンベシル酸塩を有効成分とする抗ヒスタミン薬・アレルギー性疾患治療薬です。
タリオンOD錠
タリオンOD錠は口腔内崩壊錠であり、通常のタリオン錠との生物学的同等性が確認されている抗アレルギー薬です。
【RMP資材】カナグル錠・OD錠を服用される方へ （冊子・B5・P20）
カナグル錠・OD錠を服用する際の注意点です。本剤の服用に際して患者さんにご説明の際にお使いください。
TALION AR
Allergic rhinitis medicine containing bepotastine besilate as a second-generation antihistamine, providing relief for sneezing, running nose, and stuffy nose.
タリオンAR
花粉やハウスダストなどによるくしゃみ、鼻みず、鼻づまりなどの鼻のアレルギー症状を緩和する、眠気の少ない第2世代抗ヒスタミン薬です。
タリオンＡＲ
アレルギー専用鼻炎薬。花粉やハウスダストなどによるくしゃみ、鼻みず、鼻づまりの症状を緩和します。ベポタスチンベシル酸塩を医療用と同成分・同量配合した第2世代抗ヒスタミン薬です。
タリオン錠
タリオン錠はベポタスチンベシル酸塩を有効成分とする抗ヒスタミン薬・アレルギー性疾患治療薬です。
タリオンOD錠
タリオンOD錠は口腔内崩壊錠であり、通常のタリオン錠との生物学的同等性が確認されている抗アレルギー薬です。
【RMP資材】カナグル錠・OD錠を服用される方へ （冊子・B5・P20）
カナグル錠・OD錠を服用する際の注意点です。本剤の服用に際して患者さんにご説明の際にお使いください。
Services
Discovery and preclinical-to-clinical development across therapeutic areas and modalities delivered through internal programs and external collaborations.
Manufacture and supply of prescription medicines, biologics and vaccines via company facilities and manufacturing partnerships to support commercial distribution.
Out-licensing, in-licensing, co-development and co-promotion arrangements for regional and global markets, including regulatory and market-access support.
Controlled sharing of anonymized clinical trial datasets with qualified researchers under review and governance, and maintenance of public clinical-trial registries and disclosure summaries.
Discovery and preclinical-to-clinical development across therapeutic areas and modalities delivered through internal programs and external collaborations.
Manufacture and supply of prescription medicines, biologics and vaccines via company facilities and manufacturing partnerships to support commercial distribution.
Out-licensing, in-licensing, co-development and co-promotion arrangements for regional and global markets, including regulatory and market-access support.
Controlled sharing of anonymized clinical trial datasets with qualified researchers under review and governance, and maintenance of public clinical-trial registries and disclosure summaries.
Expertise Areas
- Clinical trial management and disclosure
- Multimodal drug discovery (small molecules, biologics, ADCs)
- Vaccine research and development
- Gene and cell therapy R&D
Key Technologies
- Monoclonal antibody development
- Antibody‑drug conjugates (ADC)
- Virus‑like particle (VLP) vaccines
- Plant-based vaccine production methods
News & Updates
Regulatory approval in Japan for an additional indication relating to suppression of relapse of immunoglobulin G4‑related disease (news release).
Company received a Complete Response Letter from the U.S. FDA related to an investigational continuous subcutaneous levodopa/carbidopa infusion program.
Submission of an application in Japan seeking an additional indication for a CD19‑targeting monoclonal antibody for generalized Myasthenia Gravis.
Announcement of initiation of a Phase 1/2 clinical trial for a BRD4 degrader program in advanced solid tumors.
Regulatory submissions and interactions with FDA and EMA for a continuous subcutaneous infusion program for motor fluctuations in Parkinson's disease.
Regulatory approval in Japan for an additional indication relating to suppression of relapse of immunoglobulin G4‑related disease (news release).
Company received a Complete Response Letter from the U.S. FDA related to an investigational continuous subcutaneous levodopa/carbidopa infusion program.
Submission of an application in Japan seeking an additional indication for a CD19‑targeting monoclonal antibody for generalized Myasthenia Gravis.
Announcement of initiation of a Phase 1/2 clinical trial for a BRD4 degrader program in advanced solid tumors.
Regulatory submissions and interactions with FDA and EMA for a continuous subcutaneous infusion program for motor fluctuations in Parkinson's disease.